Tags

Type your tag names separated by a space and hit enter

Biosimilars for the treatment of psoriatic arthritis.
Expert Rev Clin Immunol 2019; 15(11):1195-1203ER

Abstract

Introduction: In recent years, biosimilars of reference adalimumab (re-ADA), etanercept (re-ETN) and infliximab (re-IFX) have been licensed. In the absence of specific controlled studies, by the extrapolation principle, biosimilars have been approved for the treatment of psoriatic arthritis (PsA).Areas covered: To assess the efficacy and safety of biosimilars in PsA, the literature, present until 30 June 2019, was reviewed. The literature search was undertaken using the PubMed database to identify English-language papers focusing on biosimilar efficacy in PsA. No specific PsA study was found, and the results were retrieved from trials on different inflammatory rheumatic diseases that were also enrolling patients with PsA. Data on re-IFX biosimilar CT-P13 and re-ETN SB4 were found, but not on re-ADA biosimilars. The results showed a trend toward a reduced efficacy of biosimilars. However, considering the small number of PsA patients, the non-statistically-powered studies, and the inappropriate outcome measures, these results could have occurred by chance.Expert opinion: The few data do not allow to draw definitive conclusions, and emerging results suggest the need of specific trials, and of rigorous registries to evaluate the efficacy and safety of biosimilars in PsA.

Authors+Show Affiliations

Rheumatology Department, Hospital of Prato, Prato, Italy.Consultant in Rheumatology, Rheumatology Clinic, Azienda USL Toscana Centro, Nuovo S. Giovanni di Dio Hospital, Florence, Italy.Consultant in Rheumatology, Rheumatology Clinic, Azienda USL Toscana Centro, Nuovo S. Giovanni di Dio Hospital, Florence, Italy.Rheumatology Department, Hospital of Prato, Prato, Italy.Rheumatology Department, Hospital of Prato, Prato, Italy.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31625769

Citation

Cantini, Fabrizio, et al. "Biosimilars for the Treatment of Psoriatic Arthritis." Expert Review of Clinical Immunology, vol. 15, no. 11, 2019, pp. 1195-1203.
Cantini F, Benucci M, Li Gobbi F, et al. Biosimilars for the treatment of psoriatic arthritis. Expert Rev Clin Immunol. 2019;15(11):1195-1203.
Cantini, F., Benucci, M., Li Gobbi, F., Franchi, G., & Niccoli, L. (2019). Biosimilars for the treatment of psoriatic arthritis. Expert Review of Clinical Immunology, 15(11), pp. 1195-1203. doi:10.1080/1744666X.2020.1682553.
Cantini F, et al. Biosimilars for the Treatment of Psoriatic Arthritis. Expert Rev Clin Immunol. 2019;15(11):1195-1203. PubMed PMID: 31625769.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Biosimilars for the treatment of psoriatic arthritis. AU - Cantini,Fabrizio, AU - Benucci,Maurizio, AU - Li Gobbi,Francesca, AU - Franchi,Giulia, AU - Niccoli,Laura, Y1 - 2019/11/01/ PY - 2019/10/19/pubmed PY - 2019/10/19/medline PY - 2019/10/19/entrez KW - Adalimumab KW - CT-P13 KW - SB4 KW - anti-TNF biosimilars KW - etanercept KW - infliximab KW - psoriatic arthritis KW - reference anti-TNFs SP - 1195 EP - 1203 JF - Expert review of clinical immunology JO - Expert Rev Clin Immunol VL - 15 IS - 11 N2 - Introduction: In recent years, biosimilars of reference adalimumab (re-ADA), etanercept (re-ETN) and infliximab (re-IFX) have been licensed. In the absence of specific controlled studies, by the extrapolation principle, biosimilars have been approved for the treatment of psoriatic arthritis (PsA).Areas covered: To assess the efficacy and safety of biosimilars in PsA, the literature, present until 30 June 2019, was reviewed. The literature search was undertaken using the PubMed database to identify English-language papers focusing on biosimilar efficacy in PsA. No specific PsA study was found, and the results were retrieved from trials on different inflammatory rheumatic diseases that were also enrolling patients with PsA. Data on re-IFX biosimilar CT-P13 and re-ETN SB4 were found, but not on re-ADA biosimilars. The results showed a trend toward a reduced efficacy of biosimilars. However, considering the small number of PsA patients, the non-statistically-powered studies, and the inappropriate outcome measures, these results could have occurred by chance.Expert opinion: The few data do not allow to draw definitive conclusions, and emerging results suggest the need of specific trials, and of rigorous registries to evaluate the efficacy and safety of biosimilars in PsA. SN - 1744-8409 UR - https://www.unboundmedicine.com/medline/citation/31625769/Biosimilars_for_the_treatment_of_psoriatic_arthritis L2 - http://www.tandfonline.com/doi/full/10.1080/1744666X.2020.1682553 DB - PRIME DP - Unbound Medicine ER -